Affiliation:
1. Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden
Abstract
ABSTRACT
The Swedish population of
Bordetella pertussis
strains was characterized from 1,247 isolates covering a whole-cell vaccine program up to 1979, a 17-year period without vaccination (1979 to 1996), and a period after the introduction of general vaccination among newborns with acellular pertussis vaccines (1997 to 2003). Strains were characterized by serotyping and genotyping of pertactin and
ptxA
and by means of pulsed-field gel electrophoresis (PFGE). With emphasis on vaccine-related markers, the vast majority of circulating strains were of nonvaccine type. There were shifts of serotype connected with shifts of vaccination program. Serotype Fim3 was most frequent during the periods with general vaccination schedules, whereas serotype Fim2 was predominant during the 17-year vaccine-free period. Pertactin 1 was predominant during the pertussis whole-cell (Pw) vaccine period but was thereafter replaced by
prn2
and has not reappeared after the introduction of acellular pertussis (Pa) vaccines.
ptxA
(1) was predominant over all three decades. There was a significant difference in the distribution of serotypes between vaccinated and unvaccinated individuals, but not for pertactin. A few PFGE profiles were predominant over the years: BpSR25 (serotype Fim3
prn1/7
) and BpSR18 (serotype Fim3
prn2
) during the Pw period, BpSR1 (serotype Fim2
prn
2) during the 17 years without general vaccination, and BpSR11 (serotype Fim3
prn
2) after the reintroduction of general vaccination in 1996. Despite differences between the pertactin and toxin types of Pa vaccines and circulating strains, there is no evidence that there is a threat, i.e., the vaccination program so far has been effective against whooping cough, and there seems to be no impact on the effectiveness of the vaccination program from the bacterial polymorphism.
Publisher
American Society for Microbiology
Reference43 articles.
1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden—protective efficacy and adverse events. Lanceti:955-960.
2. Reference System for Characterization of
Bordetella pertussis
Pulsed-Field Gel Electrophoresis Profiles
3. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination
4. Berbers G. A. M. A. B. Lafeber J. Labadie P. E. Vermeer-de Bondt D. J. A. Bolscher and A. D. Plantinga. 1999. A randomised controlled study with whole-cell or acellular pertussis vaccines in combination with regular DT-IPV vaccine and a new poliomyelitis (IPV-vero) component in children 4 years of age in The Netherlands. RIVM report 105000 001. RIVM Bilthoven The Netherlands.
5. Cassiday, P., G. Sanden, K. Heuvelman, F. Mooi, K. M. Bisgard, and T. Popovic. 2000. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J. Infect. Dis.182:1402-1408.
Cited by
84 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献